Wisconsin

LSNE’s first major acquisition was in 2018 when we brought on an additional aseptic fill finish and lyophilization facility to help meet the capacity demands of the market. After investing in renovations to improve the facility and meet all regulatory requirements, we began cGMP manufacturing in early 2019.

LSNE Madison Facility

LSNE-Madison

LSNE Madison Wisconsin Facility

Multi-Product Manufacturing Facility

Clinical Manufacturing Services

5501 Research Park Boulevard
Madison, WI 53719

CAPABILITIES

  • Acquired in 2018
  • cGMP manufacturing began in 2019
  • Drug product manufacturing of biologics and small molecules
  • Batch sizes up to 30,000 vials (liquid/lyophilized)
  • Type V Drug Master File (DMF)
  • Formulation volumes up to 200 L; custom configurations available
  • 100% non-destructive weight checks
  • On-site WFI production
  • Peristaltic pump for low shear product transfer and filtration of sensitive products
  • Diaphragm pump technology